CL BC-ECF = 0.000934 L/h). In summary, the first detailed examination using a quantitative microdialysis technique to understand the brain disposition of atomoxetine was conducted. We determined that atomoxetine brain penetration is high, movement across the BBB and BCB occur predominantly by a passive mechanism and rapid equilibration of ECF and CSF with plasma occurs.
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INTRODUCTION
Transport into the central nervous system (CNS) is essential for drugs that have pharmacological targets within the brain. The CNS exposure of a drug is determined by the blood-brain-barrier (BBB) and blood-cerebrospinal fluid-barrier (BCB) transport processes and the kinetics governing distribution and elimination. The CNS pharmacokinetics (PK) of a drug is an important determinant in the time course and intensity of effect. Non-homogeneous distribution within brain can occur due to physicochemical properties of a drug, cellular binding or the presence of active transporters at the neuronal cell membranes. Understanding brain distribution is important because it can provide valuable insights pertaining to the pharmacological actions of a drug.
It is generally accepted that only unbound drug in plasma crosses the BBB and interacts with receptors. Equilibration across the BBB and BCB can be expressed by the ratios C ECF /C uP and C CSF /C uP , respectively. When near unity is obtained from such ratios, distribution is consistent with transport by passive diffusion, or the impact of influx and efflux transport is equal. If a ratio below unity is obtained it is consistent with an active process limiting distribution such as BBB efflux, CSF bulk flow or metabolism, and a value above unity is consistent with an active influx process enhancing distribution. A ratio of ± 3-fold was meaningful to assess the contribution of a passive mechanism at the BBB based on unbound plasma and brain fractions of drugs (Kalvass et al., 2007; Maurer et al., 2005) . In addition, the brain to plasma ratios of PgP knock-out and wild-type DMD#23119 6 conduct a comprehensive in vivo evaluation of CNS penetrability and disposition of atomoxetine in rats. We sought to determine the nature and extent of transport at the BBB and BCB and to characterize brain extracellular and cellular disposition. Following steady-state infusions of atomoxetine, we collected ECF using brain microdialysis and estimated the brain extracellular and cellular concentrations of atomoxetine. Plasma, CSF and whole brain samples were also collected using conventional PK techniques and assayed for atomoxetine. A neuropharmacokinetic model was developed to characterize the CNS disposition of atomoxetine.
This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 20, 2008 as DOI: 10.1124 at ASPET Journals on November 7, 2016 dmd.aspetjournals.org Downloaded from METHODS Drugs and Chemicals. Atomoxetine HCl and its stable label, 2 H 7 -atomoxetine, were synthesized at Eli Lilly and Company. The dialysis buffer was prepared using reagent grade materials purchased from Sigma-Aldrich. The composition of the dialysis media (pH 7 -7.5) was 1.3 mM CaCl 2 , 1 mM MgCl 2 , 3 mM KCl, 147 mM NaCl, 1 mM Na 2 HPO 4 ×7H 2 0, 0.2 mM NaH 2 PO 4 ×H 2 0 and was prepared in deionized water and filtered through a 0.22 micron filter. For retrodialysis calibration studies, dialysis buffer stock solutions containing 0.1 mg/mL atomoxetine HCl and 2 H 7 -atomoxetine were prepared and stored at -70°C. One day prior to use, an aliquot of stock solution was diluted to 100 ng/ml with dialysis buffer and refrigerated. For PK studies, systemic infusion solutions of 5% dextrose in water (Braun Medical, Irvine, CA) containing 1 mg/mL atomoxetine HCl were prepared and stored at -70°C. Stock solutions of dialysis buffer containing 0.1 mg/mL 2 H 7 -atomoxetine were also prepared and stored at -70°C.
One day prior to use, an aliquot of dialysis buffer stock solution was diluted to 100 ng/ml DMD#23119 receipt, rats were acclimated for 3 days. One day before an experiment, a BAS-4 probe was inserted and perfused with dialysis buffer for 18-24 hours at a flow rate of 0.2 μL/min. The live phase portion of a study was conducted on a Culex Automated Pharmacology System (Bioanalytical Systems) that enabled timed blood and dialysate collections in awake and freely moving animals. Animals were allowed free access to food and water during the time course of sample collection. All activities were performed humanely under a protocol approved by the Eli Lilly and Company
Institutional Animal Care and Use Committee in an animal facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.
Evaluation of Plasma and Brain Binding. The atomoxetine unbound plasma fraction (f uP ) and unbound brain fraction (f uB ) was determined in a 96-well equilibrium dialysis apparatus (HTDialysis, Gales Ferry, CT) using a previously reported method (Kalvass and Maurer, 2002) . Briefly, fresh rat plasma and brain tissue were obtained the day of the study. Spectra-Por 2 membranes obtained from Spectrum Laboratories Inc. (Rancho Dominguez, CA) were conditioned in HPLC water for 15 min, followed by 30% ethanol for 15 min and 100 mM sodium phosphate pH 7.4 buffer for 15 min. Brain tissue was diluted 3-fold with 100 mM sodium phosphate (pH 7.4) buffer and homogenized with a sonic probe. Atomoxetine was added to plasma (3 µM) and brain tissue homogenate (1 µM) and 150-µl aliquots (n=3) were loaded into the 96-well equilibrium dialysis apparatus and dialyzed against an equal volume of 100 mM sodium phosphate (pH 7.4) buffer for 4.5 hr in a 155 rpm shaking water bath maintained at 37°C. Prior experience with the equilibrium dialysis apparatus indicated that equilibrium would be achieved by the end of the specified incubation period (data not shown). Following incubation, 10 µl This article has not been copyedited and formatted. The final version may differ from this version. Whole brains were homogenized in acetonitrile at a ratio of 2 ml per gram of brain and centrifuged at 3,000 rpm for 10 minutes at ambient temperature using a Beckman GPR centrifuge with a GH 3.7 swinging bucket rotor. Aliquots of 50 μL of supernatant were pipetted into a 96-well plate in duplicate for each brain. These supernatants as well as dialysate and CSF samples were analyzed for atomoxetine using standard LC-MS/MS methodology (Shimadzu HPLC with Sciex API 4000 mass spectrometer).
Retrodialysis Calibrator Validation and Loss.
2 H 7 -atomoxetine and atomoxetine are structurally similar molecules (Figure 1) . Therefore, the dialyscence properties of 2 H 7 -atomoxetine and atomoxetine should be similar across the microdialysis probe and 2 H 7 -atomoxetine should suffice as a retrodialysis calibrator for atomoxetine. To confirm, 2 H 7 -atomoxetine and atomoxetine were prepared in dialysis buffer (100 ng/mL) and coperfused through the microdialysis probe at a rate of 1 μL/min over 8 hours. Dialysate was collected at 0.5 hour intervals and the mid-point of the dialysate collection period served as the dialysate collection time. The ratio of the dialysate concentrations of atomoxetine to 2 H 7 -atomoxetine at each collection period was assessed over time.
Dialysis buffer containing 2 H 7 -atomoxetine was perfused through the microdialysis probe at a rate of 1 μL/min in PK studies. Perfusion of 2 H 7 -atomoxetine was initiated 4 hours prior to atomoxetine administration in the PK studies where atomoxetine was systemically infused for 4 hours; the total perfusion time of 2 H 7 -atomoxetine was 8 hours.
This article has not been copyedited and formatted. The final version may differ from this version. In the PK studies where atomoxetine was systemically infused for 8 hours, perfusion of 2 H 7 -atomoxetine started at time zero (along with atomoxetine). For additional study design details see section Pharmacokinetic Study Designs. The loss (L) of 2 H 7 -atomoxetine across the microdialysis probe at each collection time was estimated by the loss from the perfusate during the retrodialysis period using the equation,
where C in is the concentration of 2 H 7 -atomoxetine in the incoming perfusate (100 ng/mL) and C out is the concentration of 2 H 7 -atomoxetine in the outgoing dialysate.
Pharmacokinetic Study Designs.
Dosing Regimens. Three PK studies having different infusion dosing regimens were conducted. In study 1 (n=7 rats), an infusion loading dose was initially given at a rate of 10 mg/kg/h for 0.03 hours followed by an infusion maintenance dose given at a rate of 1.25 mg/kg/h for 3.97 hours. In studies 2 and 3 (n=8 rats each), an infusion loading dose was initially given at a rate of 14 mg/kg/h and 2.3 mg/kg/h, respectively, for 0.25 hours followed by an infusion maintenance dose given at a rate of 1.25 mg/kg/h for 7.75 hours.
In total, atomoxetine was infused for 4 hours in study 1 and for 8 hours in study 2 and 3.
The maintenance infusion rate was designed to target a steady-state plasma concentration of 250 ng/mL. In study 1, 2 and 3 the loading infusion rates were designed to approximate 0.3-, 0.6-and 3-times, respectively, the targeted steady-state plasma concentration. Time equal to zero was considered as the start time of the infusion loading dose for pharmacokinetic purposes.
This article has not been copyedited and formatted. The final version may differ from this version. Sample collections. In all 3 studies, dialysate was collected at 0.5 hour intervals starting from the time of 2 H 7 -atomoxetine perfusion through the microdialysis probe until the end of the atomoxetine maintenance infusion. The mid-point of the dialysate collection period was used as the dialysate collection time for subsequent PK analyses and for estimation of atomoxetine microdialysis recovery. Blood samples were collected at the mid-point of the dialysate collection period. The CSF and whole brain samples were collected immediately following termination of the atomoxetine maintenance infusion and after euthanization via CO 2 asphyxiation.
At each dialysate collection period, the atomoxetine ECF concentration was calculated according to the equation,
where, C ATX,t is the measured concentration of atomoxetine in the dialysate at time t and R is the recovery of atomoxetine, which is assumed to be equal to the loss of the retrodialysis calibrator, 2 H 7 -atomoxetine.
Brain Cell Concentration. The atomoxetine concentration associated with the brain cell was calculated in each rat when appropriate according to the following equation, and V BC were assumed to be 0.00029 and 0.00099 L, respectively (Mahar Doan and Boje, 2000) . The sum of V ECF and V BC was assumed to be equal to V B (Scism et al., 2000) .
Details about the determination of C B and C ECF are found below in Pharmacokinetic Analysis.
From equation 4, C BC represents the total atomoxetine concentration associated with the brain cell. To estimate the unbound atomoxetine concentration associated with the brain cell (C uBC ), the total atomoxetine concentration associated with the brain cell was multiplied by the unbound atomoxetine brain fraction as shown in the following equation,
Pharmacokinetic Analysis. At each blood sampling time, the unbound atomoxetine plasma concentration was determined by multiplying the measured atomoxetine plasma concentration by f uP . In study 1, the steady-state unbound atomoxetine plasma concentration (C uP ) and C ECF in each rat was determined by averaging the data collected from 2 -4 hours post atomoxetine administration, and the C CSF and C B in each rat was determined at 4 hours post atomoxetine administration. In study 2 and 3, the C uP and C ECF in each rat was determined by averaging the data collected from 4 -8 hours post atomoxetine administration, and the C CSF and C B in each rat was determined at 8 hours post atomoxetine administration. After obtaining these parameter values, the following ratios were calculated in each rat when data were available: C B /C P , C B /C ECF , C BC /C ECF , C uBC /C ECF , C ECF /C uP and C CSF /C uP . This Model Development. Pharmacokinetic modeling was conducted using the software NONMEM version V level 1.1 with first order condition estimation (FOCE) with interaction. The PK model describing the disposition of unbound atomoxetine is illustrated in Figure 2 . We developed a 4-compartment model consisting of a systemic compartment and a CNS compartment, which was further divided into the CSF, ECF and brain cell. The model can be described using a system of differential equations, as follows, Inter-individual variability in PK parameters were included in the model as described by the following equation,
where P ij is the j th parameter for the i th individual, P j is the typical population parameter estimate for the j th parameter and η ij is the deviation of P ij from P j in the j th parameter for the i th individual. For η i , it is assumed that the parameter is normally distributed with a mean zero and a variance (ω) to be estimated.
Residual error was estimated using a proportional error model as described by the following equation,
where C ik and Pred ik are the measured and model-predicted concentration at the k th sampling time in the i th individual, respectively. The residual error, σ, is a random variable normally distributed with mean zero and estimated variance σ 2 . The residual error describes errors arising from assay errors, sampling inaccuracies, and model misspecification.
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Plasma and Brain Binding Assessment. At 3 uM, atomoxetine was highly bound to plasma and brain with an unbound fraction of 0.13± 0.01 (n=3) and 0.013 ± 0.0007 (n=3).
Retrodialysis Calibrator Validation and Loss.
In in vivo brain microdialysis experiments 2 H 7 -atomoxetine and atomoxetine were co-perfused through the microdialysis probe and the dialysate concentrations of atomoxetine and 2 H 7 -atomoxetine were determined. Figure 3A illustrates the time-course of the ratio of atomoxetine to 2 H 7 -atomoxetine dialysate concentrations. These data demonstrate that both molecules have similar loss across the microdialysis probe because their concentration ratio is near unity. Figure 3B shows Pharmacokinetics. Figure 4 is a scatter plot of the atomoxetine plasma, CSF, ECF and whole brain concentrations across all dosing regimens. The steady-state plasma, CSF, ECF and whole brain concentrations were 268±98 (n=25), 43±14 (n=26), 17±11 (n=18) and 2790±809 (n=26), respectively. The atomoxetine steady-state concentration ratios were calculated. The C B /C P and C B /C ECF values were determined to be 11±3 (n=25) and 170±60 (n=18), respectively, and the C ECF /C uP and C CSF /C uP values were 0.7±0.4 (n=18)
This article has not been copyedited and formatted. The final version may differ from this version. (n=18) and 2.9±1.0 (n=22), respectively. A 4-compartment semi-physiological model comprised of a systemic compartment and a CNS compartment, which was further divided into the CSF, ECF and brain cell, was used to obtain PK parameter estimates unbound atomoxetine (see Figure 2) . The PK parameters estimated from the model are shown in Table 1 
DISCUSSION
The ability to cross the BBB and BCB is important for drugs with targets in the CNS. It is a commonly accepted assumption that unbound drug is the entity available for interaction with drug targets and is referred to as the free drug hypothesis. It is also assumed that unbound drug in brain is in direct contact or in equilibrium with the site of action (de Lange and Danhof, 2002) . For a compound that distributes solely by passive diffusion, at distribution equilibrium the unbound concentration in brain (C uB ) will equal the unbound concentration in plasma (C uP ) and the expected steady-state brain partition coefficient (K p,exp ) can be described using these estimates (K p,exp = f uP /f uB ). We determined f uP and f uB to be 0.131 and 0.013, respectively, (K p,exp = 10), consistent with previous literature estimates ( Mattiuz et al. 2003; Summerfield et al., 2007) . This value of K p,exp was similar to the observed steady-state brain partition coefficient (K p,obs )
following intravenous infusion of atomoxetine obtained in this study, where K p,obs = C B /C P = 11. These data further support the work of Kalvass and Maurer (2002) and the utility of predicting K p,obs from K p,exp for drugs in which BBB transport is primarily passive (K p,exp /K p,obs ≈ 1). Based on brain microdialysis, we determined the steady-state C ECF /C uP to be 0.7 and near unity. In total, these two sets of data obtained by distinct methodologies are in accordance and are consistent with the transport of atomoxetine across the BBB being primarily passive. differentiate between bound or unbound atomoxetine in the cell, and therefore, limits an understanding of the mechanism of the partitioning. We used our estimate of f uB to calculate the steady-state C uBC . To do this, we assumed that the brain tissue homogenization process and disruption of the tissue membranes did not compromise the value of f uB and that this value accurately reflects in vivo binding. We also make the distinction that f uB is a function of intracellular and/or cell membrane binding only. The C uBC /C ECF was determined to be 2.9 and substantially less than C BC /C ECF (≈ 219) showing that atomoxetine does not preferentially reside in the extracellular space. We adopted the concept of others (Kalvass et al., 2007; Maurer et al., 2005 ) based on C uBC /C ECF within 3-fold of unity to suggest that atomoxetine passively distributes within brain parenchyma.
Friden et al. (2006) demonstrated an inherent inability of the brain homogenization
technique to predict K p,obs for drugs that preferentially reside in the extracellular space in vivo. Consistent with our results for atomoxetine, the brain homogenization technique and brain microdialysis were in accordance.
We determined C CSF /C uP to be 1.7, and like the BBB, conclude that the transport of atomoxetine is primarily passive across the BCB. The concept of a sink action of CSF suggests that the C CSF /C ECF value of a drug that undergoes only passive diffusion across the BBB and BCB should be below unity. The atomoxetine C CSF /C ECF ratio was determined to be 3, which is not considered to be meaningfully different from unity.
Given the extensive partitioning of atomoxetine in brain tissue, this finding indicates that CSF bulk flow is not a significant determinant of atomoxetine residence time in the CSF.
We developed a neuropharmacokinetic model accordingly by incorporating a distributional clearance parameter at the BBB (Q BBB ) and at the BCB (Q BCB ). We
This article has not been copyedited and formatted. The final version may differ from this version. indicating the distributional clearance across the BBB was more rapid than the distributional clearance across the BCB, consistent with the larger surface area of the BBB relative to the BCB. Although definitive data are lacking, there appears to be a favored movement of drug from ECF to CSF, rather than the reverse (Rosenberg et al., 1980; Shen et al., 2004) . Therefore, in our model, CSF concentrations of atomoxetine are due to direct availability from passage across the BCB or indirectly by passage across the BBB followed by diffusion or convective flow from the ECF. Our model characterized the unidirectional transport from ECF to CSF (CL ECF-CSF ). In rats, the first-order rate constant for flow from ECF to CSF (k ECF-CSF ) and V ECF were estimated to be 0.084 h -1 and 0.00029 L, respectively (Szentistvanyi et al., 1984) . Taken as anticipated, consistent with our calculation of C uBC /C ECF (≈ 2.9).
In summary, we have carried out the first detailed examination using a quantitative microdialysis technique to understand the brain disposition of atomoxetine, a centrallyacting NET inhibitor used for the clinical treatment of ADHD. We found that atomoxetine is highly bound to brain tissue and that total brain atomoxetine concentration is not reflective of the concentration in brain ECF, the site where atomoxetine acts to inhibit NE re-uptake into the neuron. Data obtained from this study suggest that atomoxetine brain penetration is high, movement of atomoxetine across the BBB and BCB occur predominantly by a passive mechanism and rapid equilibration of ECF and CSF with plasma occurs. In addition, we developed a model to describe the neuropharmacokinetic behavior of atomoxetine, which enhances our understanding of this molecule as a therapeutic entity. 
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